Cisplatin spearheads the anticancer chemotherapeutics in present-day use although acute
toxicity is its primary impediment factor. Among a plethora of experimental medications, a …

Testicular cancer is a curable cancer. The success of physicians in curing the disease is
underpinned by multidisciplinary advances. Cisplatin-based combination chemotherapy and …

PURPOSE The long-term toxicities of chemotherapy and radiotherapy can represent a
significant burden to testicular cancer survivors. Retroperitoneal lymph node dissection …

Background The landscape of clinical trials testing risk-adapted modulations of cancer
treatments is complex. Multiple trial designs, endpoints, and thresholds for non-inferiority …

Testicular germ cell tumors (TGCTs) and sex cord-stromal tumors (SCSTs) are the most
common testicular neoplasms. The morphological spectrum of such tumors is wide, with …

Background Specific cancer types face specific clinical management challenges. Owing to
their stability, robustness and fast, easy and cost‐effective detection, microRNAs (miRNAs) …

The systemic immune-inflammation index (SIII) is a marker studied in multiple types of
urologic cancer. This systematic review evaluates the association between SIII values with …

Testicular cancer is the first solid tumor with a remarkably high cure rate. This success was
only made possible through collaborative efforts of basic and clinical research. Most patients …

PURPOSE Testicular cancer (TC) treatment is clearly associated with cardiovascular
morbidity and mortality. To enable development of preventive strategies for cardiovascular …

Purpose Ejaculatory dysfunction secondary to retrograde ejaculation or anejaculation is a
complication of retroperitoneal lymph node dissection (RPLND) for survivors of testicular …